1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Bayer Expands Kerendia Program In Competitive Heart Failure Space

 
• By Alaric DeArment

The drug maker added three investigator-initiated studies that will enroll more than 9,000 patients to the existing 6,000-patient MOONRAKER program. It has forecast peak sales of €3bn for the drug.

Bayer is expanding its clinical trial program for Kerendia in heart failure • Source: Shutterstock

Bayer AG aims to get closer to the blockbuster peak sales its executives forecast back in January for Kerendia (finerenone) with the announcement of a boost to its clinical development program to test the drug in heart failure (HF). Success in the HF program would add to the drug’s already successful launch in chronic kidney disease (CKD) associated with type 2 diabetes, a position likely to benefit from a new recommendation from the European Society of Cardiology.

On the other hand, HF is a competitive space, with three drugs approved for it included on the list of drugs facing Medicare price negotiations under the Inflation Reduction Act...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.